AU731086B2 - Mononuclear phagocytes and their use to promote axonal regeneration - Google Patents

Mononuclear phagocytes and their use to promote axonal regeneration Download PDF

Info

Publication number
AU731086B2
AU731086B2 AU66343/98A AU6634398A AU731086B2 AU 731086 B2 AU731086 B2 AU 731086B2 AU 66343/98 A AU66343/98 A AU 66343/98A AU 6634398 A AU6634398 A AU 6634398A AU 731086 B2 AU731086 B2 AU 731086B2
Authority
AU
Australia
Prior art keywords
mononuclear phagocytes
monocytes
factor
nerve
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU66343/98A
Other languages
English (en)
Other versions
AU6634398A (en
Inventor
Michal Eisenbach-Schwartz
Orly Spiegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/818,818 external-priority patent/US6117424A/en
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU6634398A publication Critical patent/AU6634398A/en
Application granted granted Critical
Publication of AU731086B2 publication Critical patent/AU731086B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU66343/98A 1997-03-14 1998-03-13 Mononuclear phagocytes and their use to promote axonal regeneration Ceased AU731086B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/818818 1997-03-14
US08/818,818 US6117424A (en) 1995-09-15 1997-03-14 Compositions of mononuclear phagocytes useful for promoting axonal regeneration
US09/041280 1998-03-11
US09/041,280 US6267955B1 (en) 1995-09-15 1998-03-11 Mononuclear phagocytes and their use to promote axonal regeneration
PCT/IL1998/000120 WO1998041220A1 (en) 1997-03-14 1998-03-13 Mononuclear phagocytes and their use to promote axonal regeneration

Publications (2)

Publication Number Publication Date
AU6634398A AU6634398A (en) 1998-10-12
AU731086B2 true AU731086B2 (en) 2001-03-22

Family

ID=26717980

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66343/98A Ceased AU731086B2 (en) 1997-03-14 1998-03-13 Mononuclear phagocytes and their use to promote axonal regeneration

Country Status (8)

Country Link
US (1) US6267955B1 (enExample)
EP (1) EP0966292A1 (enExample)
JP (1) JP2001515505A (enExample)
AU (1) AU731086B2 (enExample)
CA (1) CA2283891A1 (enExample)
IL (1) IL131888A0 (enExample)
NZ (1) NZ337813A (enExample)
WO (1) WO1998041220A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2785135B1 (fr) 1998-10-22 2000-12-29 Sfr Sa Procede de lancement d'une application par un terminal, sous commande d'un module d'identification d'abonne, module d'identification d'abonne et terminal correspondants
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
JP3607271B2 (ja) * 2001-03-12 2005-01-05 株式会社Ｇｂｓ研究所 神経損傷の治療薬
AU2002309987A1 (en) * 2001-05-25 2002-12-09 Hill-Rom Services, Inc. Modular patient room
AU2002353465B2 (en) * 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
EP1578199A2 (en) * 2002-06-14 2005-09-28 Yeda Research And Development Company, Ltd. Antigen-presenting cells for neuroprotection and nerve regeneration
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
EP1610810A2 (en) * 2003-03-28 2006-01-04 Applied Research Systems ARS Holding N.V. Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
US20090010873A1 (en) * 2004-11-29 2009-01-08 Yeda Research And Development Co. Ltd. Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
CA2737193A1 (en) * 2008-09-12 2010-03-18 Universidade Federal De Sao Paulo - Unifesp Ischemic tissue cell therapy
US20120093914A1 (en) 2008-11-24 2012-04-19 Moma Therapeutics Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration
BR112015029299A2 (pt) 2013-05-22 2017-07-25 Yeda Res & Dev subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares
CN109963940A (zh) * 2016-09-02 2019-07-02 宝生物工程株式会社 从多能干细胞获得小胶质细胞的方法
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
EP4499117A1 (en) * 2022-03-30 2025-02-05 MDX Management LLC Compositions and methods for activating immune cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157024A (en) 1977-10-16 1992-10-20 Strategic Medical Research Corporation Method of enhancing the activity of phagocytes including macrophages, modulating the cellular or humoral immune response, and reducing the adverse effects of stress in warm blooded animals
IL71440A0 (en) 1984-04-04 1984-07-31 Univ Ramot Composition for nerve regeneration
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
IL97365A0 (en) 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
IL91459A0 (en) 1989-08-28 1990-04-29 Yeda Res & Dev Oligodendrocyte inhibitory factor
US5800812A (en) 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
IL116922A0 (en) 1996-01-26 1996-05-14 Yeda Res & Dev Compositions for the regeneration of nerves in the central nervous system

Also Published As

Publication number Publication date
JP2001515505A (ja) 2001-09-18
NZ337813A (en) 2002-04-26
US6267955B1 (en) 2001-07-31
AU6634398A (en) 1998-10-12
EP0966292A1 (en) 1999-12-29
IL131888A0 (en) 2001-03-19
CA2283891A1 (en) 1998-09-24
WO1998041220A1 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
US6267955B1 (en) Mononuclear phagocytes and their use to promote axonal regeneration
Zhao et al. Intraspinal transplantation of CD34+ human umbilical cord blood cells after spinal cord hemisection injury improves functional recovery in adult rats
EP2099901B1 (en) Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells
JP4100707B2 (ja) 軸索再生を促進する単核貪食細胞の組成物及び使用方法
JP2010018627A (ja) 血管の形成ならびに血管新生および栄養因子の生産に使用するための骨髄間質細胞に由来する物質
CA2347914A1 (en) Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation
EP2579882A1 (en) Compositions and methods of treating no-option critical limb ischemia (cli)
KR20090055691A (ko) 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물
US20230210898A1 (en) Microparticle-Assisted Treg Therapy for Treatment of Tissue Injury and Fibrosis
WO2014089397A1 (en) Compositions and methods of treating and preventing pulmonary fibrosis
KR100959995B1 (ko) 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물
BRPI0620523A2 (pt) método de aumentar o potencial de implante e de atração celular, método de preparar células para transplante em um sujeito, população de células e composição farmacêutica
US20200108100A1 (en) Neural stem cell therapy for stroke
WO2019212371A1 (en) Use of microvesicles derived from stem cells in treatment of neuroinflammation, particularly induced by stroke
Jung et al. Effects of Transplantation of Human Embryonic Stem Cellson Functional Recovery in Spinal Cord Injured Rats.
HK1134688B (en) Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)